- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 10 - Treating Mild and Severe Hemophilia
During this segment, Patrick F. Fogarty, MD, discusses the treatment goals for hemophilia, based on disease severity.
Dr Fogarty defines prophylaxis, explains primary and secondary prophylaxis for the treatment of mild and severe hemophilia, and discusses the recommended target trough levels and dosage requirements based on disease severity.
He continues by discussing how treatment expectations are similar between patients, their family members, and providers. From a pediatric standpoint, Dr Fogarty stresses the importance of providing patients the best opportunity for a normal lifestyle, and explains that as longer-acting proteins continue to develop, there is an opportunity to administer intravenous therapy less frequently.
Dr Fogarty concludes by briefly discussing the benefits of the agents that are currently available to treat patients with mild and severe hemophilia, and cites a recent study that treated patients with a regimen of recombinant clotting factor 8 concentrate and revealed positive results on patients’ quality of life.
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
